Anisa Chaudhry1, Julia Selwyn2, Elizabeth Adams1, Elisa A Bradley3,4. 1. Division of Cardiovascular Medicine, Penn State Heart and Vascular Institute, Pennsylvania State University College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA, 17033, USA. 2. Department of Internal Medicine, Pennsylvania State University College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. 3. Division of Cardiovascular Medicine, Penn State Heart and Vascular Institute, Pennsylvania State University College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA, 17033, USA. ebradley3@pennstatehealth.psu.edu. 4. Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. ebradley3@pennstatehealth.psu.edu.
Abstract
PURPOSE OF REVIEW: Adult congenital heart disease (ACHD) patients have demonstrated improved survival, especially those with severely complex disease, mainly single-ventricle/Fontan physiology and those with a systemic right ventricle. We describe the heart failure phenotypes of complex CHD, reversible causes for heart failure, and considerations for advanced therapy. RECENT FINDINGS: While initially marketed for application to patients with acquired causes for heart failure, newer devices and technologies have started to be used in the ACHD population. After reversible causes for heart failure in CHD are addressed, it is reasonable to consider use of new device-based technologies and orthotopic heart transplant (OHT) for end-stage disease. New heart failure technology and organ transplant should carefully be considered and applied in complex ACHD, where there may be significant improvement in morbidity and mortality.
PURPOSE OF REVIEW: Adult congenital heart disease (ACHD) patients have demonstrated improved survival, especially those with severely complex disease, mainly single-ventricle/Fontan physiology and those with a systemic right ventricle. We describe the heart failure phenotypes of complex CHD, reversible causes for heart failure, and considerations for advanced therapy. RECENT FINDINGS: While initially marketed for application to patients with acquired causes for heart failure, newer devices and technologies have started to be used in the ACHD population. After reversible causes for heart failure in CHD are addressed, it is reasonable to consider use of new device-based technologies and orthotopic heart transplant (OHT) for end-stage disease. New heart failure technology and organ transplant should carefully be considered and applied in complex ACHD, where there may be significant improvement in morbidity and mortality.
Authors: Wendy M Book; Jennifer Gerardin; Anita Saraf; Anne Marie Valente; Fred Rodriguez Journal: Congenit Heart Dis Date: 2016-05-26 Impact factor: 2.007
Authors: Arash Salavitabar; Elisa A Bradley; Joanne L Chisolm; Jenne Hickey; Brian A Boe; Aimee K Armstrong; Curt J Daniels; Darren P Berman Journal: Catheter Cardiovasc Interv Date: 2019-10-14 Impact factor: 2.692
Authors: A C Zomer; I Vaartjes; E T van der Velde; H M Y de Jong; T C Konings; L J Wagenaar; W F Heesen; F Eerens; L H B Baur; D E Grobbee; B J M Mulder Journal: Int J Cardiol Date: 2013-04-18 Impact factor: 4.164